---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-15T09:01:55.186771'
end_time: '2025-12-15T09:07:20.642080'
duration_seconds: 325.46
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Parvovirus B19 Infection
  mondo_id: ''
  category: Viral Disease
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 13
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Parvovirus B19 Infection
- **MONDO ID:**  (if available)
- **Category:** Viral Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Parvovirus B19 Infection**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Parvovirus B19 Infection
- **MONDO ID:**  (if available)
- **Category:** Viral Disease

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Parvovirus B19 Infection**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


Disease Pathophysiology Research Template

Target Disease
- Disease Name: Parvovirus B19 Infection
- MONDO ID: 
- Category: Viral Disease

Pathophysiology description
Human parvovirus B19 (B19V) is a small, non‑enveloped single‑stranded DNA virus with a strict tropism for human erythroid progenitor cells (EPCs) in bone marrow and fetal liver. Productive infection concentrates at BFU‑E/CFU‑E stages and requires both surface determinants and permissive intracellular programs. Initial virion binding involves the neutral glycosphingolipid globoside (P antigen), while a proteinaceous receptor within the capsid VP1 unique region (VP1u) confers lineage‑specific internalization into EPCs; globoside is dispensable for initial uptake but is essential at a post‑entry step under acidic conditions that facilitate infectious endocytic trafficking (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).

Following endocytic uptake, conformational exposure of VP1u, including its PLA2‑like domain, supports endosomal escape and intracellular trafficking. Acidic environments regulate the interaction of capsids with globoside and promote capsid rearrangements linked to VP1u externalization and downstream entry steps (conti2019humanparvovirusb19 pages 36-39, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 1-3). Once the viral ssDNA enters the nucleus, it converts to dsDNA and replicates via the parvoviral rolling‑hairpin mechanism using host S‑phase factors (e.g., DNA polymerase δ, PCNA, RFC, MCM). B19V co‑opts the host DNA damage response (DDR)—primarily ATR and DNA‑PKcs—to promote replication, while NS1 and replication intermediates drive late S/G2 arrest and apoptotic death of EPCs, explaining the transient block in erythropoiesis and aplastic crises (ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).

Intrinsic determinants of permissivity include erythropoietin (EPO) signaling and STAT5 activation, with hypoxic conditions enhancing STAT5A activity and B19V replication in EPCs. NS1’s replication and transactivation domains cooperate with phosphorylated STAT5 and MCM components to support viral DNA synthesis (ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13). Beyond EPCs, B19V can infect endothelial cells and other non‑erythroid cell types in abortive or low‑level fashion, which may contribute to vascular and inflammatory manifestations and provides a reservoir for persistence (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5). Immune‑complex deposition underlies classical rash and arthropathy phenotypes during acute infection (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32).

In pregnancy, P antigen on trophoblast and placental transport pathways allow maternal‑fetal transmission, particularly early in gestation. Fetal infection of erythroid tissues produces severe anemia and hydrops from profound erythropoietic suppression and high‑grade viremia. Secondary viremia after bone‑marrow infection can be extremely high—“viral titers than can reach 10^12 viruses/mL” (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32). Myocardial involvement is linked to infection of endothelial cells in the heart with associated inflammatory injury; persistence of B19V genomes in cardiac tissues has been documented, though the extent to which persistence/reactivation drives disease remains under study (arvia2024parvovirusb19in pages 4-5, reggiani2022agenomeediting pages 28-32).

Key concepts and definitions with current understanding
- Tropism and receptor biology: Globoside (P antigen) mediates attachment and acts as an essential intracellular factor for infectious trafficking under acidic pH; a VP1u‑specific protein receptor controls lineage‑specific internalization into human EPCs (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29, ganaie2018recentadvancesin pages 1-3, ros2020thevp1uof pages 15-17).
- Endosomal escape and trafficking: VP1u harbors a PLA2‑like domain; low pH promotes capsid rearrangements and interaction with globoside that enable post‑entry steps toward nuclear import and productive infection (conti2019humanparvovirusb19 pages 36-39, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 1-3).
- Replication dependencies: B19V depends on the host S‑phase machinery and DDR (ATR, DNA‑PKcs); EPO/STAT5 signaling and hypoxia enhance replication in EPCs (ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
- Cytopathology: NS1 and replication trigger late S/G2 arrest and apoptosis of EPCs, transiently suppressing erythropoiesis and causing anemia/aplastic crises (ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
- Persistence and non‑erythroid infection: Low‑level, often abortive infection of endothelial and other cells supports persistence and may contribute to extra‑hematologic disease (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5).
- Immune‑complex disease: Rash and arthralgia are attributed to immune‑complex formation and deposition during the seroconversion phase (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32).

Recent developments and latest research (prioritized 2023–2024)
- Updated receptor/entry model integrating VP1u receptor specificity with globoside’s essential post‑entry role under acidic conditions, refining how pH‑dependent globoside interactions guide infectious endocytic trafficking (arvia2024parvovirusb19in pages 12-13). 
- Contemporary reviews emphasize endothelial involvement, tissue persistence, and immunopathogenic links in rheumatologic contexts, consolidating non‑erythroid impacts (arvia2024parvovirusb19in pages 4-5).

Current applications and real‑world implementations
- Mechanistic insights into EPO/STAT5 and hypoxia are used to optimize ex vivo EPC culture systems for B19V study and to interpret clinicopathologic patterns of transient aplasia (ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
- Recognition of immune‑complex–mediated rash/arthropathy and the marrow‑restricted cytopathology informs diagnostic interpretation of serology and marrow morphology in suspected B19V syndromes (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32).

Expert opinions and analysis from authoritative sources
- Synthesis articles highlight that globoside alone does not define tropism; rather, a VP1u receptor determines strict erythroid specificity while globoside supports post‑entry steps—reconciling widespread globoside expression with narrow tissue permissivity (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
- Reviews of parvovirus–host DDR crosstalk emphasize ATR and DNA‑PKcs as central enablers of replication, linking NS1‑driven cell‑cycle perturbations to EPC death and clinical anemia (ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3).

Relevant statistics and data from recent studies
- Secondary viremia following marrow infection can reach approximately 10^12 virions/mL, consistent with profound cytopathic anemia and transmissibility (reggiani2022agenomeediting pages 28-32).

Core Pathophysiology
- Primary mechanisms: lineage‑restricted entry via VP1u receptor; globoside‑dependent post‑entry trafficking under acidic conditions; VP1u‑PLA2–facilitated endosomal escape; reliance on host S‑phase/DDR; NS1‑driven S/G2 arrest and apoptosis of EPCs; immune‑complex–mediated rash/arthropathy; non‑productive endothelial infection supporting persistence (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13, reggiani2022agenomeediting pages 28-32).
- Dysregulated pathways: JAK‑STAT signaling (EPO/STAT5); DDR (ATR/Chk1, DNA‑PKcs); cell‑cycle checkpoints (late S/G2) (ganaie2018recentadvancesin pages 1-3, ganaie2018recentadvancesin pages 7-8, arvia2024parvovirusb19in pages 12-13).
- Affected cellular processes: endocytosis and endosomal trafficking, nuclear import, viral genome replication, apoptosis of EPCs, immune‑complex formation (conti2019humanparvovirusb19 pages 36-39, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 1-3, ganaie2018recentadvancesin pages 7-8, reggiani2022agenomeediting pages 28-32).

Key Molecular Players
- Genes/Proteins (HGNC):
  - EPOR (EPO receptor) and EPO–STAT5A/STAT5B axis enabling replication-permissive transcriptional state (ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
  - DDR kinases: ATR (HGNC:8807) and PRKDC/DNA‑PKcs (HGNC:9436) required for replication signaling (ganaie2018recentadvancesin pages 7-8).
  - MCM complex (e.g., MCM2‑7; HGNC family) cooperating with pSTAT5 in replication (arvia2024parvovirusb19in pages 12-13).
  - Viral NS1 (B19V nonstructural protein) driving cell‑cycle arrest and apoptosis; VP1/VP2 capsid proteins with VP1u RBD/PLA2 activities (ganaie2018recentadvancesin pages 7-8, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 1-3).
- Chemical Entities (CHEBI):
  - Erythropoietin (CHEBI:18222) signaling; glycosphingolipid globoside (Gb4; glycosphingolipid class CHEBI:24401) as attachment/trafficking cofactor (ganaie2018recentadvancesin pages 1-3, conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29).
- Cell Types (CL):
  - Human erythroid progenitor cell (CL term; BFU‑E/CFU‑E) as permissive target; endothelial cell as abortive/persistent site (ganaie2018recentadvancesin pages 1-3, conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5).
- Anatomical Locations (UBERON):
  - Bone marrow (UBERON:0002371), fetal liver (UBERON:0002107), placenta (UBERON:0001987), heart/endothelium (UBERON:0000948/cardiac vasculature) (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5).

Biological Processes (for GO annotation)
- Viral entry into host cell (GO:0046718) and endocytosis (GO:0006897) with pH‑dependent globoside interactions (conti2019humanparvovirusb19 pages 36-39, ganaie2018recentadvancesin pages 1-3).
- Endosomal escape and intracellular trafficking; Golgi/endosomal transport (GO:0005794/GO:0005768 context) linked to VP1u conformational changes (conti2019humanparvovirusb19 pages 36-39, ros2020thevp1uof pages 15-17).
- Viral genome replication (GO:0019079) via rolling‑hairpin; DNA damage response (GO:0006974); cell cycle arrest (GO:0007050) (ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3).
- JAK‑STAT cascade (GO:0007259) in EPO/STAT5‑dependent permissivity (ganaie2018recentadvancesin pages 1-3, arvia2024parvovirusb19in pages 12-13).
- Apoptotic process (GO:0006915) of EPCs; immune complex clearance/deposition relevant to rash/arthropathy (ganaie2018recentadvancesin pages 7-8, reggiani2022agenomeediting pages 28-32).

Cellular Components
- Endosome (GO:0005768) and Golgi apparatus (GO:0005794) in post‑entry trafficking; nucleus (GO:0005634) for replication; viral capsid (GO:0019028) with VP1u exposure (conti2019humanparvovirusb19 pages 36-39, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 1-3).

Disease Progression
- Sequence: respiratory acquisition and viremia → marrow homing and EPC infection → dsDNA conversion and rolling‑hairpin replication → DDR activation, late S/G2 arrest, EPC apoptosis → transient aplastic crises or severe anemia (in high‑risk/hemolytic states) → seroconversion with immune‑complex manifestations (rash, arthropathy); in pregnancy, fetal marrow/liver infection leads to high viremia, severe anemia and hydrops; non‑erythroid/endothelial infection may contribute to vascular and cardiac inflammation; low‑level persistence in tissues can follow resolution (conti2019humanparvovirusb19 pages 36-39, ganaie2018recentadvancesin pages 7-8, ganaie2018recentadvancesin pages 1-3, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5).

Phenotypic Manifestations
- Hematologic: transient aplastic crisis, pure red‑cell aplasia, severe anemia in fetuses/hemolytic disorders; marrow erythroid hypoplasia with giant pronormoblasts (HP terms: Anemia HP:0001903; Aplastic crisis HP:0001873) (conti2019humanparvovirusb19 pages 36-39, ganaie2018recentadvancesin pages 1-3).
- Dermatologic/Immunologic: erythema infectiosum rash and arthralgia due to immune‑complex deposition (HP:0000988, HP:0002829) (conti2019humanparvovirusb19 pages 36-39, reggiani2022agenomeediting pages 28-32).
- Cardiovascular: myocarditis/vascular inflammation associated with endothelial infection/persistence (HP:0001638) (arvia2024parvovirusb19in pages 4-5).
- Pregnancy/Fetal: fetal anemia and hydrops fetalis (HP:0001877, HP:0001790) from targeted fetal erythropoiesis suppression and high viremia (conti2019humanparvovirusb19 pages 36-39).

Evidence items (PMIDs/links/dates)
- Arvia et al., 2024, Microorganisms. Parvovirus B19 in Rheumatic Diseases. DOI: 10.3390/microorganisms12081708; URL: https://doi.org/10.3390/microorganisms12081708 (arvia2024parvovirusb19in pages 4-5, arvia2024parvovirusb19in pages 12-13).
- Ganaie & Qiu, 2018, Frontiers in Cellular and Infection Microbiology. Recent Advances in Replication and Infection of Human Parvovirus B19. DOI: 10.3389/fcimb.2018.00166; URL: https://doi.org/10.3389/fcimb.2018.00166 (ganaie2018recentadvancesin pages 1-3, ganaie2018recentadvancesin pages 7-8).
- Conti, 2019 (doctoral thesis). Human Parvovirus B19: from the development of a reverse genetics system to antiviral strategies. DOI: 10.6092/unibo/amsdottorato/8773; URL: https://doi.org/10.6092/unibo/amsdottorato/8773 (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29).
- Ros et al., 2020, Viruses. The VP1u of Human Parvovirus B19: A Multifunctional Capsid Protein with Biotechnological Applications. DOI: 10.3390/v12121463; URL: https://doi.org/10.3390/v12121463 (ros2020thevp1uof pages 15-17).
- Reggiani, 2022 (doctoral thesis). A genome editing approach to the study of Parvovirus B19. DOI: 10.48676/unibo/amsdottorato/10210; URL: https://doi.org/10.48676/unibo/amsdottorato/10210 (reggiani2022agenomeediting pages 28-32).

Direct quotes (with support)
- “viral titers than can reach 10^12 viruses/mL” during secondary viremia (reggiani2022agenomeediting pages 28-32).

Plan status
- Completed objectives: 1 (literature identification); 2–4 addressed in synthesis above; 5 completed by delivering the cited report.

Inline source attributions
Key mechanistic claims on receptor/entry, endosomal escape, replication cofactors, DDR reliance, erythroid cytopathology, immune‑complex disease, persistence, pregnancy/fetal hydrops, and endothelial involvement are supported by the sources cited above (conti2019humanparvovirusb19 pages 36-39, conti2019humanparvovirusb19 pages 26-29, ganaie2018recentadvancesin pages 1-3, ros2020thevp1uof pages 15-17, ganaie2018recentadvancesin pages 7-8, arvia2024parvovirusb19in pages 12-13, reggiani2022agenomeediting pages 28-32, arvia2024parvovirusb19in pages 4-5).

References

1. (conti2019humanparvovirusb19 pages 36-39): Ilaria Conti. Human parvovirus b19: from the development of a reverse genetics system to antiviral strategies. Text, Jan 2019. URL: https://doi.org/10.6092/unibo/amsdottorato/8773, doi:10.6092/unibo/amsdottorato/8773. This article has 0 citations and is from a peer-reviewed journal.

2. (conti2019humanparvovirusb19 pages 26-29): Ilaria Conti. Human parvovirus b19: from the development of a reverse genetics system to antiviral strategies. Text, Jan 2019. URL: https://doi.org/10.6092/unibo/amsdottorato/8773, doi:10.6092/unibo/amsdottorato/8773. This article has 0 citations and is from a peer-reviewed journal.

3. (ganaie2018recentadvancesin pages 1-3): Safder S. Ganaie and Jianming Qiu. Recent advances in replication and infection of human parvovirus b19. Frontiers in Cellular and Infection Microbiology, Jun 2018. URL: https://doi.org/10.3389/fcimb.2018.00166, doi:10.3389/fcimb.2018.00166. This article has 104 citations and is from a poor quality or predatory journal.

4. (arvia2024parvovirusb19in pages 12-13): Rosaria Arvia, Maria A. Stincarelli, Elisabetta Manaresi, Giorgio Gallinella, and Krystyna Zakrzewska. Parvovirus b19 in rheumatic diseases. Microorganisms, 12:1708, Aug 2024. URL: https://doi.org/10.3390/microorganisms12081708, doi:10.3390/microorganisms12081708. This article has 15 citations and is from a poor quality or predatory journal.

5. (ros2020thevp1uof pages 15-17): Carlos Ros, Jan Bieri, and Remo Leisi. The vp1u of human parvovirus b19: a multifunctional capsid protein with biotechnological applications. Viruses, 12:1463, Dec 2020. URL: https://doi.org/10.3390/v12121463, doi:10.3390/v12121463. This article has 25 citations and is from a poor quality or predatory journal.

6. (ganaie2018recentadvancesin pages 7-8): Safder S. Ganaie and Jianming Qiu. Recent advances in replication and infection of human parvovirus b19. Frontiers in Cellular and Infection Microbiology, Jun 2018. URL: https://doi.org/10.3389/fcimb.2018.00166, doi:10.3389/fcimb.2018.00166. This article has 104 citations and is from a poor quality or predatory journal.

7. (reggiani2022agenomeediting pages 28-32): Alessandro Reggiani. A genome editing approach to the study of parvovirus b19. Text, Jan 2022. URL: https://doi.org/10.48676/unibo/amsdottorato/10210, doi:10.48676/unibo/amsdottorato/10210. This article has 0 citations and is from a peer-reviewed journal.

8. (arvia2024parvovirusb19in pages 4-5): Rosaria Arvia, Maria A. Stincarelli, Elisabetta Manaresi, Giorgio Gallinella, and Krystyna Zakrzewska. Parvovirus b19 in rheumatic diseases. Microorganisms, 12:1708, Aug 2024. URL: https://doi.org/10.3390/microorganisms12081708, doi:10.3390/microorganisms12081708. This article has 15 citations and is from a poor quality or predatory journal.